

**Genotype 3
Treatment-Naive Patients
All Patients**

TABLE 128: SVR GENOTYPE 3 TREATMENT-NAIVE: RELATIVE RISKS AND RISK DIFFERENCE FOR ALL TREATMENT COMPARISONS — RANDOM EFFECTS MODEL

TREATMENT	REFERENCE	RR (95% CRI)	RD % (95% CRL)
SOF24 + RBV24	PR 48	1.31 (1.21 to 1.37)	21.82 (14.74 to 25.97)
DCV12 + SOF12		1.37 (1.26 to 1.42)	26.08 (18.69 to 29.05)
DCV12 + SOF12	SOF24 + RBV24	1.05 (0.96 to 1.13)	4.16 (-3.50 to 11.09)
Random effect model	Residual deviance	10.56 vs. 10 data points	
	Deviance information criteria	66.132	
Fixed effect model	Residual deviance	11.32 vs. 10 data points	
	Deviance information criteria	66.119	

Cri = credible interval; DCV = daclatasvir; PR = pegylated interferon plus ribavirin; RBV = ribavirin; RD = risk difference; RR = relative risk; SOF = sofosbuvir; SVR = sustained virologic response; vs. = versus.
Note: Please refer to Treatment Regimen Nomenclature table for description of dosages.